No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.

Thoralf LangeChristian NiederwieserArthur GilRainer KrahlUlrich von GrünhagenHaifa Kathrin Al-AliKathleen Jentsch-UllrichClaudia SpohnVolker LaknerMichael AssmannChristian JunghanssMichael CrossRüdiger HehlmannMichael DeiningerMarkus PfirrmannDietger Niederwieser

Published in: Leukemia & lymphoma (2020)

IM/HU combination was more potent in selectively inhibiting CML cells in vitro, but not superior to IM in vivo. (NCT02480608).

Keyphrases

chronic myeloid leukemia
induced apoptosis
signaling pathway
oxidative stress
cell proliferation
cell death